Financial Performance - The company reported a significant increase in revenue, achieving a total of $500 million for the first half of 2023, representing a 25% year-over-year growth[4]. - The company provided guidance for the next quarter, projecting revenue growth of 15% to 20%, expecting to reach between $575 million and $600 million[4]. - Operating expenses were reduced by 5%, totaling $150 million, contributing to improved profitability[4]. - The company's operating revenue for the reporting period was ¥149,603,691.12, a decrease of 85.89% compared to ¥1,060,557,926.68 in the same period last year[105]. - Net profit attributable to shareholders was ¥108,219,740.04, down 63.71% from ¥298,186,325.38 year-on-year[105]. - The net profit after deducting non-recurring gains and losses was ¥57,878,391.61, reflecting a decline of 78.23% from ¥265,810,862.35 in the previous year[105]. - The weighted average return on equity decreased to 1.96%, down from 6.74% in the previous year[105]. - The company reported a basic earnings per share of ¥0.1804, down 64.91% from ¥0.5141 in the same period last year[105]. User Engagement and Market Expansion - User data showed a rise in active users to 2 million, up from 1.5 million in the previous year, indicating a 33% increase[4]. - Market expansion efforts include entering three new international markets, projected to increase overall market share by 10%[4]. - The company plans to enhance its digital marketing strategy, aiming for a 20% increase in customer engagement metrics[4]. Research and Development - The company is investing $10 million in R&D for new technologies aimed at enhancing product efficiency and user experience[4]. - The company has established multiple core technology platforms for vaccine research and production, including the "Influenza Virus Vaccine R&D and Large-Scale Production Technology Platform" and "Multi-Valent Vaccine Technology Platform" to enhance its R&D capabilities[52]. - The company plans to continue investing in R&D for new vaccine products to enrich its product pipeline and create new profit growth points[52]. - The company’s R&D investment in the reporting period was approximately 52 million CNY, a decrease of 37.41% compared to the previous year[142]. Vaccine Development and Production - The company is actively developing mRNA vaccines, including mRNA influenza vaccines, to leverage the advantages of mRNA technology in response to public health emergencies[52]. - The four-valent influenza vaccine (children's formulation) received drug registration approval in February 2022 and was launched in the market during the 2022 influenza season[52]. - The company has obtained drug registration certificates for the freeze-dried human rabies vaccine and adsorbed tetanus vaccine in February 2023, and is currently engaged in production and sales[52]. - The company achieved a total of 72 batches of flu vaccine approvals by the end of the reporting period, maintaining the leading position in the domestic market[111]. - The company has a production capacity of 100 million doses of quadrivalent flu vaccine annually, supported by six production workshops[114]. - The company's revenue from influenza vaccines was RMB 148,147,883.90, reflecting a decrease of 85.97% compared to the same period last year, while the gross margin for this product was 102.01%[160]. Financial Management and Fundraising - The company raised a total of RMB 2,275,768,800.00 from the issuance of 40,010,000 shares at a price of RMB 56.88 per share, with net proceeds after underwriting fees amounting to RMB 2,254,768,800.00[149]. - As of June 30, 2023, the company has an unused balance of RMB 1,205,410,266.56 in raised funds, with RMB 930,000,000.00 invested in financial products and the remainder in dedicated accounts[149]. - The total amount of raised funds is 227,576.88 million CNY, with 8,821.82 million CNY invested during the reporting period[194]. - Cumulative investment of raised funds reached 108,514.98 million CNY, with no changes in the use of raised funds reported[194]. - The company has utilized 88,218,158.58 CNY of the raised funds, with a remaining balance of 1,205,410,266.56 CNY in cash management products[194]. Risk Factors - The vaccine industry is characterized by a lengthy R&D cycle and multiple regulatory approval stages, which pose risks that could delay progress or impact revenue generation[59]. - The company faces risks of significant profit decline or even losses due to increasing competition as other companies launch similar products[179]. - The company faces risks related to market competition and the complexity of vaccine production processes, which may impact its operational performance[199]. Compliance and Governance - The company has not faced any penalties or violations during the reporting period[78]. - The company emphasizes standardized operations in vaccine R&D, production, and sales, and will enhance safety education and academic promotion related to vaccination[179]. - The company has established a comprehensive quality assurance system to ensure the safety and effectiveness of its vaccine products[200].

证券代码：301207 证券简称：华兰疫苗 公告编号：2023-029 华兰生物疫苗股份有限公司 关于参加河南辖区上市公司 2023年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，华兰生物疫苗股份有限公司（以下简称 "公司"）定于 2023 年 5 月 18 日（周四）16:00-17:20 参加在全景网举办的"真 诚沟通 传递价值"河南辖区上市公司 2023 年投资者网上集体接待日活动，本次 活 动 将 采 用 网 络 远 程 的 方 式 举 行 ， 投 资 者 可 登 录 " 全 景 · 路 演 天 下 " （http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员有：公司财务总监兼董事会秘书吕成玉 先生，证券事务代表李伦先生，欢迎广大投资者积极参与。 特此公告。 华兰生物疫苗股份有限公司董事会 2023 年 5 月 13 日 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥144,762,101.26, a significant increase of 892.96% compared to ¥14,578,885.25 in the same period last year[7] - Net profit attributable to shareholders was ¥93,967,811.66, marking an increase of 11,156.09% from a loss of ¥849,919.03 in the previous year[7] - Basic earnings per share rose to ¥0.2349, compared to a loss of ¥0.0023 per share in the same quarter last year, reflecting a growth of 10,313.04%[7] - Operating profit for the quarter was 105,903,077.92, compared to an operating loss of 7,161,665.06 in Q1 2022[35] - Total profit for the quarter reached 105,961,150.80, a turnaround from a total loss of 7,297,154.69 in the previous year[35] Cash Flow - The net cash flow from operating activities was ¥192,546,198.76, a 472.36% increase from a negative cash flow of ¥51,709,044.15 in Q1 2022[20] - Cash inflow from investment activities totaled ¥1,134,548,139.19, up from ¥398,011,360.96 in the prior period, marking an increase of approximately 185.5%[43] - The company recorded a cash outflow from financing activities of 1,500,000.01, compared to an outflow of 3,837,499.99 in the previous year[37] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,102,287,203.11, a slight increase of 0.38% from ¥7,075,517,368.83 at the end of the previous year[7] - Total current assets decreased to ¥4,063,364,164.46 from ¥4,192,738,083.14, a decline of about 3.1%[26] - Total liabilities decreased to 1,504,541,278.82 from 1,578,941,039.38 year-over-year[32] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period is 16,683[22] - The top shareholder, Hualan Biological Engineering Co., Ltd., holds 67.50% of shares, totaling 270,000,000 shares[22] - The company has a total of 364,002,650 restricted shares, with 58,001,975 shares released during the period[29] Inventory and Expenses - The company reported a significant increase in inventory, which rose by 92.25% to ¥321,355,281.16, primarily due to an increase in work-in-progress[10] - The company experienced a 3927.65% increase in selling expenses, totaling ¥43,659,973.15, due to higher service fees associated with increased vaccine sales[16] - Total operating costs amounted to ¥90,312,538.22, compared to ¥39,965,718.51 in the prior period, indicating an increase of about 126.5%[41] Investment and Income - The company’s investment income increased by 286.61% to ¥16,723,286.29, attributed to higher returns from financial investments[16] - The total non-recurring gains and losses amounted to ¥25,934,688.48 after tax, indicating a strong performance in non-operational areas[14] - The company achieved other income of ¥4,397,479.86, compared to ¥1,094,230.65 in the previous period, representing an increase of approximately 301.5%[41] Research and Development - Research and development expenses for the current period were ¥28,994,998.34, down from ¥35,308,146.72 in the previous period, indicating a decrease of about 17.9%[41] Future Outlook - The company plans to continue expanding its market presence and developing new products and technologies[30]

（二）出席人员：公司董事兼总经理安文珏女士、公司财务总监兼董事会秘书 吕成玉先生、公司独立董事杨东升先生、公司保荐代表人贾鹏先生。 华兰生物疫苗股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 华兰生物疫苗股份有限公司（以下简称"公司"）于 2023 年 3 月 30 日在巨潮资 讯网（www.cninfo.com.cn）披露了《公司 2022 年年度报告》。为便于广大投资者进 一步了解公司 2022 年度的经营情况及未来发展规划，公司将于 2023 年 4 月 14 日 （周五）15:00-17:00 通过深圳证券交易所"互动易"平台以网络方式举办 2022 年度 业绩说明会（以下简称"本次说明会"），现将有关事项公告如下： 一、本次说明会的安排 （一）召开时间：2023 年 4 月 14 日 15:00-17:00 证券代码：301207 证券简称：华兰疫苗 公告编号：2023-019 （ 三 ） 接 入 方 式 ： 投 资 者 可 登 陆 深 圳 证 券 交 易 所 " 互 动 易 " 平 台 （ht ...

Financial Performance - Total revenue for 2022 was approximately ¥1.83 billion, a decrease of 0.23% compared to ¥1.83 billion in 2021[21]. - Net profit attributable to shareholders was approximately ¥519.63 million, down 16.32% from ¥620.97 million in 2021[21]. - The net profit after deducting non-recurring gains and losses was approximately ¥451.68 million, a decrease of 22.84% from ¥585.41 million in 2021[21]. - Cash flow from operating activities was approximately ¥288.66 million, down 49.30% from ¥569.33 million in 2021[21]. - Basic earnings per share were ¥1.32, a decrease of 23.41% from ¥1.72 in 2021[21]. - Total operating revenue for 2022 was ¥1,825,640,965.76, a slight decrease of 0.23% compared to ¥1,829,813,885.72 in 2021[46]. - Vaccine products accounted for 99.56% of total revenue, with a revenue of ¥1,817,533,244.46, down 0.38% from ¥1,824,557,525.53 in 2021[46]. - The company produced 26,862,365 vaccine doses in 2022, an increase of 6.08% from 25,323,527 doses in 2021, while sales volume decreased by 6.40% to 14,542,643 doses[49]. - The gross profit margin for vaccine products was 88.49%, with a slight increase of 0.29% compared to the previous year[48]. - The company reported a net profit of ¥517,894,411.06 for the year 2022, with a distributable profit of ¥1,807,308,630.23 after accounting for previous undistributed profits[126]. Cash Flow and Investments - Cash flow from operating activities was approximately ¥288.66 million, down 49.30% from ¥569.33 million in 2021[21]. - Operating cash inflow decreased by 24.38% to ¥1,530,912,497.16, while net cash flow from operating activities fell by 49.30% to ¥288,662,214.13 due to reduced sales collections[60][61]. - Investment cash inflow increased by 64.84% to ¥5,157,189,418.12, but net cash flow from investment activities was negative at -¥1,755,650,532.72, a 60.79% increase in outflow[60][61]. - Financing cash inflow surged by 219.35% to ¥2,554,768,800.00, resulting in a net cash flow from financing activities of ¥1,952,237,131.98, an increase of 582.28%[60][61]. - Cash and cash equivalents increased by 305.26% to ¥485,248,813.39, reversing a previous decline[60][61]. - The proportion of cash and cash equivalents to total assets rose significantly from 2.91% at the beginning of the year to 8.48% at year-end[62]. Product Development and Market Position - The company is the largest influenza vaccine production base in China, with a current vaccination rate of only 3%, indicating significant growth potential in the domestic market[34]. - The mRNA technology platform is rapidly developing, showing significant advantages in vaccine development, with potential applications in various viral vaccines[33]. - The company has multiple vaccine products in the research or registration process, which will enhance its competitive edge as the product line expands[34]. - The company maintained its leading position in the domestic market with 103 batches of flu vaccine approvals in 2022, including 77 batches of quadrivalent flu vaccine (adult type) and 14 batches (children's type)[38]. - The company is actively developing new products, including mRNA flu vaccines, and has established an mRNA vaccine research platform to enhance its technological reserves for long-term development[42]. - The company has launched a new vaccine product line, which is projected to generate CNY 150 million in sales within the first year[108]. Research and Development - Research and development expenses decreased by 6.58% to ¥134,639,873.00 compared to ¥144,128,186.81 in 2021[56]. - R&D investment amounted to ¥136,276,778.35 in 2022, representing 7.46% of operating revenue, a decrease from 8.04% in 2021[58]. - The company has established multiple core technology platforms for vaccine development, including mRNA vaccine technology and adenovirus vector vaccine technology[81]. - The company is investing CNY 200 million in R&D for new vaccine technologies in 2023, focusing on mRNA vaccine development[108]. Governance and Compliance - The company maintains a robust governance framework, ensuring compliance with relevant laws and regulations, and promoting transparency in operations[89]. - The company has established a comprehensive internal control system in accordance with relevant laws and regulations, enhancing its governance structure[130][131]. - The company strictly adheres to legal requirements for information disclosure, ensuring that all shareholders have equal access to information, thereby enhancing the quality and transparency of annual report disclosures[91]. - The company has no significant discrepancies between its governance practices and the regulations set forth by the China Securities Regulatory Commission[92]. Risks and Challenges - The company faces risks due to a relatively single product structure, with over 90% of revenue coming from flu vaccine sales, making it vulnerable to market fluctuations[83]. - The development of new vaccines involves lengthy R&D cycles and regulatory approvals, posing risks of delays and financial losses[84]. - Quality control is critical, as any lapses in production or distribution could lead to product quality issues, affecting both health outcomes and the company's reputation[85]. - Adverse reactions from vaccinations could lead to significant reputational damage and regulatory consequences if not managed properly[85]. Future Outlook - The company has set a performance guidance for 2023, projecting a revenue growth of 15%[99]. - Looking ahead, Hualan Biological expects a revenue growth target of 20% for 2023, aiming for CNY 1.8 billion[109]. - The company plans to expand its operations into three new international markets by the end of 2023[197]. - The company is exploring strategic acquisitions to enhance its market position, targeting a 10% increase in market share[199]. Shareholder Engagement and Dividends - The company plans to distribute a cash dividend of ¥3 per 10 shares, with a capital reserve increase of 5 shares for every 10 shares held[4]. - A cash dividend of ¥3 per 10 shares (totaling ¥120,003,000.00) was distributed to shareholders, with the cash dividend amount representing 100% of the total distributable profit[124][126]. - The company has established a stock incentive plan, granting 3.4 million restricted stocks to 28 eligible participants as part of its employee incentive measures[129].

Financial Performance - The company's revenue for Q3 2022 was ¥499,312,414.08, a decrease of 63.87% compared to the same period last year[6]. - The net profit attributable to shareholders for Q3 2022 was ¥206,521,700.73, down 62.93% year-on-year[6]. - The net profit after deducting non-recurring gains and losses was ¥188,217,171.83, reflecting a decline of 65.83% compared to the previous year[6]. - The company reported a basic earnings per share of ¥0.5192, down 66.45% year-on-year[6]. - Net profit for the current period was ¥504,708,026.11, a decrease of 4.4% from ¥528,169,121.73 in the previous period[32]. - Basic and diluted earnings per share for the current period were 1.2904, compared to 1.4671 in the previous period[35]. Assets and Liabilities - The total assets at the end of Q3 2022 reached ¥7,173,842,560.89, an increase of 58.59% from the end of the previous year[6]. - The total assets increased to ¥7,173,842,560.89 from ¥4,523,446,917.50, showing strong growth in the company's asset base[28]. - The total liabilities decreased slightly to ¥1,696,840,935.11 from ¥1,715,354,421.76, indicating improved financial stability[28]. - The equity attributable to shareholders increased by 95.04% year-on-year, amounting to ¥5,477,001,625.78[6]. - The equity attributable to shareholders of the parent company rose to ¥5,477,001,625.78 from ¥2,808,092,495.74, reflecting strong retained earnings growth[28]. Cash Flow - The cash flow from operating activities showed a net outflow of ¥35,484,779.81, a significant decrease of 111.81% compared to the previous year[11]. - Cash inflow from operating activities totaled 967,781,400.50, down from 1,411,702,881.33 in the previous period, representing a decrease of approximately 31%[36]. - Net cash flow from operating activities was -35,484,779.81, a significant decline from 300,587,782.41 in the previous period[36]. - Cash inflow from investment activities was 4,331,189,120.42, compared to 2,265,110,874.30 in the previous period, indicating an increase of approximately 91%[39]. - Net cash flow from investment activities was -1,147,864,950.82, worsening from -644,256,999.76 in the previous period[39]. - Cash inflow from financing activities amounted to 2,554,768,800.00, up from 800,000,000.00 in the previous period[39]. - Net cash flow from financing activities was 1,964,579,300.01, compared to 591,522,222.12 in the previous period, showing a substantial increase[39]. - The ending balance of cash and cash equivalents was 896,022,620.53, up from 599,048,768.52 in the previous period[39]. - The company reported a net increase in cash and cash equivalents of 781,229,569.38, compared to 247,853,004.77 in the previous period[39]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,460[15]. - The largest shareholder, Hualan Biological Engineering Co., Ltd., holds 67.50% of shares, totaling 270,000,000 shares[15]. - The total number of preferred shareholders is not applicable, indicating no preferred shares were issued[18]. - The company has a total of 366,071,060 restricted shares at the end of the reporting period[21]. - The company plans to lift restrictions on 270,000,000 shares by August 18, 2025, which were issued before the initial public offering[18]. - The top ten shareholders do not have any known relationships or agreements that would classify them as acting in concert[17]. Expenses and Investments - The company experienced a 32.88% increase in sales expenses, totaling ¥636,720,642.53, due to increased marketing efforts[11]. - Total operating costs amounted to ¥1,007,106,441.39, up from ¥807,739,933.50, reflecting a significant increase in sales expenses[29]. - Research and development expenses were ¥110,099,858.88, slightly up from ¥108,705,277.49, indicating continued investment in innovation[29]. - The company has invested in new product development and market expansion strategies, although specific figures are not disclosed in the provided content[20]. Tax and Future Outlook - The company reported a significant increase in deferred income tax assets, rising to ¥197,459,746.95 from ¥182,899,117.57, suggesting potential future tax benefits[28]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[31]. Audit Status - The third quarter report was not audited[40].

Financial Performance - Hualan Biological reported a revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[21]. - The company achieved a net profit of RMB 300 million, which is a 10% increase compared to the same period last year[21]. - The company's operating revenue for the reporting period reached ¥1,060,557,926.68, a significant increase of 9,624.76% compared to the same period last year[29]. - Net profit attributable to shareholders was ¥298,186,325.38, marking a remarkable increase of 1,128.93% year-over-year[29]. - The net profit after deducting non-recurring gains and losses was ¥265,810,862.35, reflecting a 732.78% increase compared to the previous year[29]. - The company reported a total revenue of ¥249,502.74 million, an increase from ¥224,420.31 million, with a net profit of ¥94,552.37 million[66]. - The total profit for the first half of 2022 was ¥337,023,951.29, a significant turnaround from a loss of ¥47,665,924.26 in the first half of 2021[185]. - The company's basic earnings per share for the first half of 2022 was ¥0.7712, compared to a loss per share of -¥0.0805 in the same period of 2021[185]. Market Expansion and Product Development - User data indicates that the company has expanded its customer base by 20% in the first half of 2022, reaching a total of 1 million users[21]. - Hualan Biological plans to invest RMB 500 million in R&D for new vaccine technologies in the upcoming year[21]. - The company is targeting a revenue growth of 20% for the full year 2022, driven by new product launches and market expansion[21]. - Hualan Biological has successfully launched a new quadrivalent influenza vaccine, which is expected to capture 15% of the market share within the first year[21]. - The company is actively exploring potential acquisition opportunities to strengthen its market position and expand its product portfolio[21]. - The company is focused on expanding its market presence in the four-valent influenza vaccine sector, which has seen increased competition from other vaccine manufacturers[81]. - The company is actively developing multiple vaccines, including rabies and tetanus vaccines, to diversify its product offerings and mitigate risks associated with a narrow product range[79]. Financial Management and Investments - The company has established multiple core technology platforms for vaccine research and development, including an mRNA vaccine platform, and is actively conducting preliminary research on mRNA influenza vaccines[48]. - The company has invested ¥382,380 million in entrusted financial management, with a remaining balance of ¥261,661.68 million in unexpired financial products[71]. - The company reported investment income of ¥25,946,910.34, a substantial increase from ¥4,677,100.13 in the prior year, showcasing improved investment performance[185]. - The company received 2,254,768,800.00 in cash from financing activities, a substantial increase from 300,000,000.00 in the previous year[200]. - The net cash flow from financing activities was 2,167,012,633.35, compared to 95,511,388.82 in the first half of 2021[200]. Risk Management - Hualan Biological has identified key risks including regulatory changes and market competition, and has outlined strategies to mitigate these risks[21]. - The company identified risks related to a single product structure, with over 90% of revenue coming from influenza vaccines, which could impact profitability if market demand fluctuates[79]. - The company faces increasing competition in the vaccine market, which may lead to significant profit declines or losses[83]. - The company has established a comprehensive quality assurance system to mitigate risks related to product quality and ensure vaccine safety and efficacy[83]. Cash Flow and Financial Position - The net cash flow from operating activities for the first half of 2022 was -53,783,108.36, a significant decrease compared to 331,140,552.23 in the same period of 2021[194]. - The cash and cash equivalents increased by ¥893,034,043.65, a rise of 989.27% compared to ¥81,984,685.40 in the previous year[49]. - The company's total assets increased by 60.71% to ¥7,269,667,171.01 from the end of the previous year[29]. - The company's current assets amounted to RMB 5,013,289,419.91, up from RMB 2,529,227,166.81 at the start of the year, indicating a growth of approximately 98.5%[164]. - The company's accounts receivable rose to RMB 1,921,901,740.48, compared to RMB 1,438,966,174.92, reflecting an increase of approximately 33.5%[164]. Corporate Governance and Compliance - The company has not distributed cash dividends or bonus shares for the half-year period[90]. - The company has not engaged in derivative investments or entrusted loans during the reporting period, maintaining a conservative financial strategy[73][74]. - The company did not experience any bankruptcy reorganization matters during the reporting period[106]. - The company is committed to maintaining transparency and compliance with regulatory requirements as indicated by its disclosures[138].

Financial Performance - The company's revenue for Q1 2022 was ¥14,578,885.25, representing a 32.67% increase compared to ¥10,989,066.50 in the same period last year[5] - The net profit attributable to shareholders was -¥849,919.03, an improvement of 79.39% from -¥4,124,253.29 year-over-year[5] - The company reported a basic earnings per share of -¥0.0023, improving by 80.00% from -¥0.0115 in the same period last year[5] - The weighted average return on equity was -0.02%, an improvement from -0.19% year-over-year[5] - The total profit (loss) for the period was -7,297,154.69, an improvement from -10,534,334.31 in the previous period, indicating a reduction in losses[35] - The net profit (loss) attributable to the parent company was -849,919.03, compared to -4,124,253.29 in the previous period, showing a significant decrease in losses[35] Cash Flow - The net cash flow from operating activities was -¥51,709,044.15, a decline of 121.25% compared to ¥243,311,535.68 in the previous year[5] - Cash inflows from operating activities totaled 271,671,609.62, down from 595,713,661.48 in the previous period, reflecting a decline in cash generation[38] - Cash outflows from operating activities amounted to 323,380,653.77, compared to 352,402,125.80 in the previous period, indicating a decrease in cash outflows[38] - The net cash flow from investing activities was -469,050,302.04, worsening from -279,933,599.29 in the previous period[41] - Cash inflows from financing activities reached 2,254,768,800.00, compared to 300,000,000.00 in the previous period, indicating a substantial increase in financing[41] - The net increase in cash and cash equivalents was 1,730,171,953.82, significantly higher than 260,860,019.70 in the previous period[41] Assets and Liabilities - Total assets increased by 49.14% to ¥6,746,296,460.98 from ¥4,523,446,917.50 at the end of the previous year[5] - Total liabilities decreased slightly to CNY 1,694,850,780.34 from CNY 1,715,354,421.76, a reduction of 1.1%[28] - The equity attributable to the parent company increased significantly to CNY 5,051,445,680.64 from CNY 2,808,092,495.74, representing an increase of 79.3%[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 34,703, with the top ten shareholders holding 67.50% of the shares[12] - The top shareholder, Hualan Biological Engineering Co., Ltd., holds 270 million shares, representing 67.50% of the total shares[12] - The company has a total of 36 million shares held by Cyber Creator Limited, accounting for 9.00% of the shares[12] - The company has a total of 270 million shares under lock-up conditions, which are set to be released on August 18, 2025[16] Operational Highlights - The company raised ¥2,250,931,300.01 from financing activities, a significant increase of 656.66% compared to ¥297,482,083.31 in the previous year[7] - The company experienced a 75.18% decrease in operating costs, amounting to ¥234,777.35, attributed to vaccine returns and increased costs from a wholly-owned subsidiary[7] - The company reported a 77.56% increase in investment income, reaching ¥4,325,579.33, due to higher financial management returns[11] - Research and development expenses increased to CNY 35,308,146.72, up from CNY 31,389,740.69, indicating a growth of 12.3%[32] - The company plans to continue expanding its market presence and investing in new product development[30] - Future guidance indicates a focus on enhancing operational efficiency and exploring potential mergers and acquisitions[30] Inventory and Receivables - Inventory increased by 209.19% to ¥332,096,723.22, primarily due to an increase in raw materials and work-in-progress[7] - The company reported accounts receivable of approximately 1.206 billion RMB, down from 1.439 billion RMB at the beginning of the year[21] - The company has 1.029 billion RMB in trading financial assets, an increase from 825.82 million RMB at the beginning of the year[21] - The company's inventory increased to approximately 332.10 million RMB from 107.41 million RMB at the beginning of the year[21] Market Activity - The company has successfully registered a quadrivalent influenza virus split vaccine for children in February 2022[20]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2021, representing a year-on-year increase of 15%[18] - The net profit attributable to shareholders was RMB 300 million, which is a 10% increase compared to the previous year[18] - The company's operating revenue for 2021 was ¥1,829,813,885.72, a decrease of 24.59% compared to 2020[25] - The net profit attributable to shareholders for 2021 was ¥620,972,414.89, down 32.86% from the previous year[25] - The net profit after deducting non-recurring gains and losses was ¥585,412,142.79, reflecting a decline of 34.88% year-over-year[25] - The company achieved a total operating revenue of approximately ¥1.83 billion in 2021, a decrease of 24.59% compared to ¥2.43 billion in 2020[57] - Vaccine products accounted for 99.71% of total revenue, with a revenue of approximately ¥1.82 billion, down 24.63% year-on-year[57] - The gross profit margin for vaccine products was 88.20%, a decrease of 1.41% compared to the previous year[60] - The company reported a cash dividend of 2.00 yuan per 10 shares, totaling 80,002,000 yuan, which represents 100% of the distributable profit of 1,412,479,097.25 yuan[159] Market Expansion and Product Development - User data indicates that the company has expanded its customer base by 20% over the past year, reaching a total of 1 million users[18] - The company is focusing on the development of a new quadrivalent influenza vaccine, expected to launch in Q3 2022[18] - Market expansion efforts have led to a 25% increase in sales in international markets, particularly in Southeast Asia[18] - The management has set a revenue growth target of 20% for 2022, driven by new product launches and market penetration strategies[18] - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product portfolio[18] - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[129] - New product development includes a vaccine that is expected to enter the market by Q3 2022, with an estimated production capacity of 100 million doses annually[129] Research and Development - The company has allocated RMB 150 million for research and development in 2022, aiming to enhance vaccine efficacy and safety[18] - The company has established multiple core technology platforms to enhance its vaccine research and development capabilities[50] - The R&D expenditure for the year was 200 million RMB, accounting for 13% of total revenue, reflecting a commitment to innovation[129] - The company is accelerating the R&D progress of its projects, with several vaccines, including rabies and tetanus vaccines, already submitted for production approval[96] Operational Efficiency and Challenges - The company reported a net cash flow from operating activities of ¥569,328,674.62, a decrease of 17.93% compared to the previous year[25] - The sales volume of vaccine products decreased by 28.51% to approximately 15.54 million doses in 2021, compared to 21.73 million doses in 2020[61] - The inventory of vaccine products increased by 181.73% to approximately 9.50 million doses, primarily due to a decline in influenza vaccine sales during the overlapping vaccination seasons[61] - The company reported a decrease in operating costs by 14.37% year-on-year, attributed to the decline in sales volume[60] Governance and Compliance - The company has implemented a transparent governance structure, ensuring compliance with legal and regulatory requirements, and maintaining operational independence[106] - The board of directors operates efficiently with established committees, enhancing decision-making processes and governance standards[107] - The company has not experienced any changes in its board of directors, supervisors, or senior management during the reporting period[120] - The company has a complete procurement, production, and sales system, functioning as an organic whole[112] - The company has not engaged in any related party transactions that would compromise its independence[112] Social Responsibility and Market Position - The company is recognized as the largest influenza vaccine production base in China, with six listed products covering various vaccine categories[178] - The company emphasizes a commitment to social responsibility, aiming to harmonize economic and social benefits[179] - The company has actively participated in several national key scientific research projects related to vaccine development[179] Future Commitments and Shareholder Relations - The company plans to repurchase shares if the closing price falls below the audited net asset value per share from the previous fiscal year, with a repurchase amount not exceeding RMB 10 million per transaction[195] - The company commits to adhere to the measures for compensating diluted immediate returns[198] - The company will ensure compliance with legal obligations and disclosure requirements regarding related transactions[192]